AMSNYSEServices-Medical LaboratoriesFiscal year ends December 31
AMERICAN SHARED HOSPITAL SERVICES
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.26−0.02 (-1.20%)
Close on Oct 19, 2026
- Market cap
- $8.69M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
18.0%−7.0 pts over 5 years
Operating margin
-12.8%+40.3 pts over 5 years
Net margin
-5.5%+34.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.9% | +12.5% | +9.5% | +5.4% | |
| Gross profit | -44.9% | -15.5% | +2.5% | -2.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 4.5% | -31.2% | -6.3% | |
| Return on assets | 1.6% | -14.5% | -2.7% | |
| Current ratio | 0.91 | 0.88 | 0.76 | |
| Debt to equity | 0.34 | 0.26 | 0.72 | |
| Net debt to EBITDA | 0.44× | -0.44× | 6.51× | |
| Interest coverage | 1.9× | -9.0× | -2.3× | |
| Capex to revenue | 5.6% | 2.6% | 27.2% | |
| Diluted shares | 6M | 6M | 7M |
Where the cash went
Fiscal 2021 to 2025, five years combined
American Shared Hospital Services generated $22.49M from operations and spent $23.91M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$22.49M
Used
$23.91M
Capital expenditure$23.91M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-5.5%
×Asset turnover0.49×
×Equity multiplier2.35×
=Return on equity, FY2025-6.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -5.5% | 0.49× | 2.35× | -6.3% |
| FY2024 | 7.7% | 0.52× | 2.27× | 9.1% |
| FY2023 | 2.9% | 0.46× | 2.08× | 2.8% |
| FY2022 | 6.7% | 0.44× | 2.15× | 6.4% |
| FY2021 | 1.1% | 0.40× | 2.27× | 1.0% |
| FY2020 | -39.6% | 0.37× | 2.15× | -31.2% |
| FY2019 | 3.2% | 0.37× | 2.18× | 2.6% |
| FY2018 | 5.2% | 0.34× | 2.36× | 4.2% |
| FY2017 | 9.8% | 0.33× | 2.62× | 8.5% |
| FY2016 | 5.0% | 0.33× | 2.76× | 4.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$1.55M
- Cash generatingOperating cash flow above zero$3.10M
- Return on assets improvedROA up on the prior year4.5% → -2.6%
- Earnings backed by cashOperating cash flow above net income$3.10M vs -$1.55M
- Less leverageLong-term debt to assets fell28.8% → 0.0%
- Better liquidityCurrent ratio rose2.52 → 0.76
- No dilutionShare count did not rise7M → 7M
- Gross margin improvedGross margin up on the prior year32.41% → 18.03%
- More efficientAsset turnover rose0.59 → 0.47